Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes
13 janv. 2022 07h00 HE
|
Helsinn Healthcare S.A.
Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes Strategy focuses on developing and commercializing a differentiated pipeline of...
Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron)
02 déc. 2021 04h30 HE
|
Helsinn Healthcare S.A.
Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) Lugano, Switzerland, December 2, 2021 – Helsinn Group, a fully integrated, global...
Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD
24 juin 2021 08h30 HE
|
Helsinn Healthcare S.A.
Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD Lugano, Switzerland, June 24, 2021 – Helsinn, a Swiss Biopharmaceutical...
Helsinn appoints Mary Lynne Hedley to Board of Directors
29 avr. 2021 03h00 HE
|
Helsinn Healthcare S.A.
Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
Helsinn appoints Mary Lynne Hedley to Board of Directors
29 avr. 2021 03h00 HE
|
Helsinn Healthcare S.A.
Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting
18 mars 2021 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
12 janv. 2021 03h30 HE
|
Helsinn Healthcare S.A.
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss...
Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay
30 juil. 2020 03h00 HE
|
Helsinn Healthcare S.A.
Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay Biasca, Switzerland, July 30, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare...
Helsinn announces launch of oral formulation of Akynzeo® in China
09 juin 2020 03h30 HE
|
Helsinn Healthcare S.A.
Helsinn announces launch of oral formulation of Akynzeo® in China Lugano, Switzerland, June 9, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease...
Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States
02 juin 2020 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States Lugano, Switzerland, June 2, 2020 – Helsinn, a Swiss...